Keywords: Control Rod Worth; Reactivity Balance; Reactivity Feedback; Small Modular Reactor; Soluble Boron Free; BA; Burnable Absorber; BOC; Beginning of Cycle; CEA; Control Element Assembly; CZP; Cold Zero Power; EOC; End of Cycle; FA; Fuel Assembly; FTC; Fuel Tem
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ACC; anterior cingulate cortex; AEDs; ntiepileptic drugs; BPRS; Brief Psychiatric Rating Scale; CBZ; carbamazepine; CZP; clonazepam; EP+DS; epilepsy patients with depressive symptoms; EP-DS; epilepsy patients without depressive symptoms; FC; functional co
Keywords: AED; antiepileptic drug; CBZ; carbamazepine; CLB; clobazam; CZP; clonazepam; ESL; eslicarbazepine acetate; GBP; gabapentin; ILAE; International League Against Epilepsy; LCM; lacosamide; LEV; levetiracetam; LTG; Lamotrigine; Na; sodium; OXC; oxcarbazepine;
Keywords: BAFME; benign adult familial myoclonus epilepsy; CZP; clonazepam; JLA; jerk-locked back averaging; SEP; somatosensory evoked potential; VPA; sodium valproate; Cortical tremor; Epileptic seizure; Cortical hyperexcitability; Giant somatosensory evoked poten
Keywords: BCH; 2-Amino-2-norbornanecarboxylic acid; CBZ; carbamazepine; CLB; clobazam; CZP; clonazepam; GBP; gabapentin; LAT; l-type amino acid transporter; LC/MS/MS; liquid chromatography/tandem mass spectrometry; LEV; levetiracetam; LTG; lamotrigine; NZP; nitraze
Keywords: MTX; methotrexate; TNF; tumor necrosis factor; IL; interleukin; CTLA4; cytotoxic T-lymphocyte antigen 4; IFX; infliximab; ADA; adalimumab; GLM; golimumab; CZP; certolizumab pegol; ETN; etanercept; TCZ; tocilizumab; ABA; abatacept; RTX; rituximab; UTK; ust
Keywords: ADA; adalimumab; AEs; adverse events; AZA; azathioprine; CI; confidence interval; Cy; cyclosporine; CNS; central nervous system; CS; corticosteroids; CYC; cyclophosphamide; CZP; certolizumab pegol; ePOST; Extrapulmonary Physician Organ Severity Tool; ETN;
Keywords: AED; antiepileptic drug; BNF; British National Formulary; BZD; benzodiazepine; CLB; clobazam; CZP; clonazepam; CPRD; Clinical Practice Research Database; ISAC; Independent Scientific Advisory Committee; LGS; Lennox-Gastaut syndrome; MHRA; Medicines and
Keywords: ADA; adalimumab; CD; Crohn disease; CDAI; Crohn's Disease Activity Index; CrI; credible interval; CZP; certolizumab pegol; HR; hazard ratio; IBD; inflammatory bowel disease; IFX; infliximab; IL-12/23; interleukin 12/23; NAT; natalizumab; OR; odds ratio;
Keywords: A; absenteeism; ADA; adalimumab; CD; Crohn's disease; CPC; conventional proctocolectomy and Brooke ileostomy; CZP; certolizumab pegol; HPWAW; hours per week actually worked; HPWFP; productivity and hours per week fully productive; IBD; inflammatory bowel
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48Â weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)
Keywords: anti-TNF; anti-tumor necrosis factor; certolizumab pegol; chronic plaque psoriasis; CIMPASI-1; CIMPASI-2; phase 3 trial; CZP; certolizumab pegol; DLQI; Dermatology Life Quality Index; FcRn; neonatal Fc receptor; PASI; Psoriasis Area and Severity Index;
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48Â weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)
Keywords: anti-TNF; anti-tumor necrosis factor; certolizumab pegol; chronic plaque psoriasis; CIMPACT; etanercept; phase 3 trial; CZP; certolizumab pegol; FcRn; neonatal Fc receptor; PASI; Psoriasis Area and Severity Index; PASI 50; â¥50% reduction in PASI from
Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: AÂ Meta-analysis
Keywords: Crohn's Disease; Biologics; Pharmacokinetics; Serum Drug Level; ADA; antidrug antibodies; CD; Crohn's disease; CI; confidence interval; CZP; certolizumab pegol; ELISA; enzyme-linked immunosorbent assay; HMSA; homogenous mobility shift assay; IBD; infl
Solid state synthesis and structural refinement of polycrystalline phases: Ca1−2xZr4M2xP6−2xO24 (MMo, x = 0.1 and 0.3)
Keywords: CZP; Rietveld refinement; GSAS; XRD and SEM
Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease
Keywords: Biologics; Real-World Effectiveness; Database Analysis; Propensity Matching; ADA; adalimumab; aHR; adjusted hazard ratio; CD; Crohn's disease; CI; confidence interval; CZP; certolizumab pegol; IBD; inflammatory bowel disease; ICD-9; International Classi
Study of power distribution in the CZP, HFP and normal operation states of VVER-1000 (Bushehr) nuclear reactor core by coupling nuclear codes
Keywords: CZP; Flux; HFP; Power distribution; Reactor;
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Keywords: CDAI; MUSIC Trial; PK Study; TNF Inhibitor; BMI; body mass index; CD; Crohn's disease; CDAI; Crohn's Disease Activity Index; CDEIS; Crohn's Disease Endoscopic Index of Severity; CI; confidence interval; CRP; C-reactive protein; CZP; certolizumab pegol; MU
The core design of ALFRED, a demonstrator for the European lead-cooled reactors
Keywords: CZP; cold zero-power; DBA; design basis accidents; DEC; design extension conditions; DPA; deterministic and phenomenological analyses; ELFR; European lead-cooled fast reactor; FA; fuel assembly; HFP; hot full-power; HZP; hot zero-power; ISAM; integrated s
Vagus nerve stimulation for drug-resistant Epilepsia Partialis Continua: Report of four cases
Keywords: EPC; Epilepsia Partialis Continua; VNS; vagus nerve stimulation; RE; Rasmussen's encephalitis; ACDs; anticonvulsant drugs; SE; status epilepticus; MDZ; midazolam; CBZ; carbamazepine; OXC; oxcarbamazepine; TPM; topiramate; LVT; leviracetam; VPA; valproic a
American Gastroenterological Association Institute Technical Review on the Use of Thiopurines, Methotrexate, and Anti-TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease
Keywords: ACG; American College of Gastroenterology; ADA; adalimumab; AZA; azathioprine; BSG; British Society of Gastroenterology; CD; Crohn's disease; CDAI; Crohn's Disease Activity Index; CI; confidence interval; CZP; certolizumab pegol; ECCO; European Crohn's an
Placental Transfer of Anti-Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease
Keywords: Ulcerative Colitis; Crohn's Disease; Treatment; Safety; Pregnancy; ADA; adalimumab; BCG; bacillus Calmette-Guérin; CZP; certolizumab pegol; ELISA; enzyme-linked immunosorbent assay; IBD; inflammatory bowel disease; IFX; infliximab; Ig; immunoglobulin;
Substance P release in response to cardiac ischemia from rat thoracic spinal dorsal horn is mediated by TRPV1
Keywords: AEA; N-arachidonoylethanolamide; AMT; anandamide membrane transporter; AU; arbitrary units; BPM; beats per minute; BSA; bovine serum albumin; C2; cervical 2; CAP; capsaicin; CISAN; cardiac ischemic-sensitive afferent neurons; CoAO; coronary artery occlusi
Research ReportTransient receptor potential vanilloid 1 channels modulate the anxiolytic effect of diazepam
Keywords: AEA; anandamide; ANOVA; analysis of variance; AM404; N-(4-hydroxyphenyl)-arachidonylethanolamide; CAP; capsaicin; CB1; cannabinoid receptor type 1; CZP; capsazepine; DMSO; dimethylsulfoxide; DZP; diazepam; FAAH; fatty acid amide hydrolase; GABARAP; GABA r
Synthesis and crystal structure of nanocrystalline phase: Ca1−xMxZr4P6O24 (M = Sr, Ba and x = 0.0–1.0)
Keywords: Nanoceramic; CZP; Powder XRD; GSAS; Rietveld refinement; Microstructure
Special ArticleReport of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects
Keywords: mAbs; monoclonal antibodies; IFX; infliximab; ADA; adalimumab; CZP; Certolizumab pegol; PNR; primary non response to anti-TNF agent; LOR; loss of response to anti-TNF agent; ATI; antibodies to infliximab; ATA; antibodies to adalimumab; FcγR; Fc gamma rec